The list of 2026 National-level Key “Little Giant” Enterprises was recently announced, with AccuMedical securing a place as the only medical consumables company among the Beijing enterprises selected in this round. After years of focus on neurointervention, this recognition at the national level affirms the company’s strengths in innovation, industry leadership and sustainable, high-quality development, and further reinforces its position in the high-end neurointerventional device sector.
The National-Level Key “Little Giant” designation is jointly awarded by the Ministry of Industry and Information Technology and the Ministry of Finance. It represents the highest tier of recognition in China’s program for cultivating specialized, sophisticated, distinctive and innovative enterprises. Candidates must already be recognized as national-level “Little Giant” enterprises and focus on priority industrial chains, the “Six Foundations” of industry, strategic emerging industries or industries of the future. These enterprises undertake critical tasks to address weaknesses and fill gaps in industrial chains, serving as key business drivers of new quality productive forces.
The recognition carries significance on two levels: it represents authoritative national recognition of AccuMedical’s technological capabilities and position in the industrial chain, and makes the company eligible for national-level policy support and resources.
Since its establishment in 2017, AccuMedical has focused on neurointerventional medical devices, pursuing independent innovation in response to unmet clinical needs. The company has built a comprehensive portfolio spanning the diagnosis and treatment of hemorrhagic and ischemic stroke, as well as neurointerventional access. To date, 10 of its products have been approved for marketing, including the Lattice® series of Flow Diverters, the Grism® Stent Retriever with a Closed Distal End, the Attractor® Aspiration Catheter, the Cosine® series of Distal Access Catheters, and the Sine® series of Microcatheters.
From its recognition as a Beijing Specialized, Sophisticated, Distinctive, and Innovative SME in 2022, to its designation as a National-level “Little Giant” Enterprise in 2024, and now its selection as a National-level Key “Little Giant” Enterprise, AccuMedical has made steady progress. Guided by its commitment to genuine innovation and practical application, the company continues to bring new solutions to a neurointerventional field long dominated by established international players, advancing in this highly specialized sector.
Building on the supportive industrial development environment created by this AccuMedical will continue to make technological innovation its driving force and clinical value its compass. The company will focus on advancing critical technologies in neurointervention and strengthening the development, translation and commercialization of innovative medical devices, contributing to the self-reliance and high-quality development of China’s high-end medical device industry.